Injectafer denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Injectafer as Duplicate Therapy

Humana may issue a duplicate-therapy denial for Injectafer (ferric carboxymaltose) when it determines that another iron replacement agent already dispensed or authorized during the same benefit period sufficiently covers the clinical need. This denial type does not dispute that iron deficiency exists — it disputes whether a second iron product is medically necessary when one is already on file.

This denial is worth appealing because Injectafer has a distinct pharmacokinetic profile and clinical indication recognized in the FDA-approved prescribing label. Your prescriber's judgment that the previously authorized agent is inadequate — or that the clinical situation calls for this specific formulation — is documentable and reviewable.

## Federal Appeal Framework

Under ACA §2719 (for non-grandfathered plans), you are entitled to a full internal appeal followed by binding external review by an Independent Review Organization (IRO). ERISA §503 requires a full-and-fair review for employer-sponsored plans, including access to the evidence used in the denial. The external-review request window is typically four months from the denial notice. If your clinical situation is urgent, request expedited external review, which must be decided within 72 hours.

## Concrete Appeal Steps

1. Request the written denial letter and the complete clinical criteria Humana applied. 2. Ask Humana's pharmacy or medical director to specify exactly which previously authorized agent they regard as therapeutically equivalent. 3. Have your prescriber document in writing why the prior agent is clinically insufficient (inadequate response, tolerability, administration constraints, or a distinct indication covered by Injectafer's label but not the comparator's). 4. File the internal appeal within Humana's stated deadline (usually 180 days from denial). 5. If denied internally, file for external review within four months.

## Documentation to Gather

• Diagnosis confirmation: Recent labs, physician diagnosis notes confirming the underlying condition driving iron deficiency.
• Prior-treatment history: Dates of the previously authorized iron agent, doses administered, documented response or adverse outcome — showing it was inadequate or differently indicated.
• Clinical severity: Chart notes quantifying symptom burden and functional impact.
• Prescriber medical-necessity letter: Explicitly addresses why this is not a duplicate — i.e., the prior agent does not fulfill the same clinical function in this patient's specific case.

## Criteria-Mapping Structure

Obtain the FDA-approved Injectafer prescribing label and Humana's published medical/coverage policy for IV iron replacement. Build a side-by-side table:

| Humana/label requirement | Supporting chart fact | |---|---| | Confirmed diagnosis of iron deficiency | [Insert lab date + result] | | Prior agent tried and found inadequate | [Insert agent, dates, documented outcome] | | Injectafer indication distinct from prior agent | [Prescriber letter reference] |

Address every criterion Humana cited in the denial. Appeals that map chart evidence directly to each policy requirement have the strongest track record at external review.